Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GCS-100 in Diabetic Chronic Kidney Disease
NCT02312050Phase 2Unknown
- Sponsor
- La Jolla Pharmaceutical Company
- Start
- Mar 2015
- Primary completion
- Sep 2016
- Modality
- Polysaccharide, Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GCS-100 in diabetic kidney disease (DKD) (4 arms), sponsored by La Jolla Pharmaceutical Company. Primary endpoint: Change in estimated Glomerular Filtration Rate at 26 weeks. Status: unknown.
02
Drugs
GCS-100
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT02312050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02312050.